This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pacheco, D. Y. Articles by Gibson, N. W. Search for Related Content PubMed PubMed Citation Articles by Pacheco, D. Y. Articles by Gibson, N. W.

Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines¹

Laboratory of Pharmacology, AMC Cancer Research Center, Denver, Colorado 80214

1,7-Heptanediol disulfamate (hepsulfam, NSC 329680) is a new anticancer agent which is currently undergoing phase I clinical trials. The mechanism of action of this compound is not clear at this time. We have recently shown that hepsulfam was more toxic to L1210 leukemia cells than was busulfan. Consistent with the difference in toxicity, we found that hepsulfam induced DNA interstrand cross-links in L1210 mouse leukemia cells, whereas busulfan did not. In the present study, we have found that hepsulfam was more cytotoxic to two human leukemia cell lines (HL-60 and K562) and to two human colon carcinoma cell lines (BE and HT-29) than was busulfan. As in L1210 cells, hepsulfam induced a higher level of DNA interstrand cross-links than busulfan. Both compounds induced DNA-protein cross-links. Hepsulfam was also more cytotoxic to the human leukemia cell lines when the concentrations were reduced 10-fold and the duration of drug exposure was increased to 12 h. This more accurately reflects the drug exposures that human leukemia cells may encounter in vivo. Under these 12-h drug exposures, hepsulfam was still able to form DNA interstrand and DNA-protein cross-links, whereas busulfan was only able to form DNA-protein cross-links. These results show that busulfan and hepsulfam react with DNA differently and that hepsulfam is a more potent cytotoxic agent.

¹ Supported by NIH Grant CA 50582.

² Present address: Division of Pharmaceutics, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033.

³ Present address: Toxicology Department, Sterling Research Group, 81 Columbia Turnpike, Rensselaer, NY 12144.

⁴ To whom requests for reprints should be addressed, at School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, Ca 90033.

Received 5/ 4/90. Accepted 9/ 4/90.

This article has been cited by other articles:

				S. D. Mertins, T. G. Myers, S. L. Holbeck, W. Medina-Perez, E. Wang, G. Kohlhagen, Y. Pommier, and S. E. Bates In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity Mol. Cancer Ther., July 1, 2004; 3(7): 849 - 860. [Abstract] [Full Text] [PDF]

				P. Morales-Ramirez, T. Vallarino-Kelly, V. L. Cruz-Vallejo, R. Lopez-Iturbe, and H. Alvaro-Delgadillo In vivo kinetics of micronuclei induction by bifunctional alkylating antineoplastics Mutagenesis, May 1, 2004; 19(3): 207 - 213. [Abstract] [Full Text] [PDF]

				G. R. Westerhof, R. E. Ploemacher, A. Boudewijn, I. Blokland, J. H. Dillingh, A. T. McGown, J. A. Hadfield, M. J. Dawson, and J. D. Down Comparison of Different Busulfan Analogues for Depletion of Hematopoietic Stem Cells and Promotion of Donor-Type Chimerism in Murine Bone Marrow Transplant Recipients Cancer Res., October 1, 2000; 60(19): 5470 - 5478. [Abstract] [Full Text]